Listed Advanced Medical Solutions (AMS) has confirmed it is in discussions with TA Associates, a US private equity firm investment team specialising in five target industries: technology, financial services, healthcare, consumer and business services, regarding a possible takeover.
AMS, a developer and manufacturer of tissue-healing technology, has said there is no certainty that a firm offer will be made.
News reports point to TA Associates making a bid of 280 pence per share, valuing the company at around £600m (US$810m). The company’s shares are quoted today at 261.10 pence per share, up from 220 pence on Friday, over 18% higher.
In March, AMS reported group revenue increased by 29% to £228.9m in 2025 (2024: £177.5m) and adjusted EBITDA increased by 24% to £49.9m (2024: £40.2m).
